

Pharmaceutical Pipeline – Key Events in 2022*

POTENTIAL APPROVALS US/EU

- ✓ US **CARVYKTI (Ciltacabtagene autoleucel)**
- ✓ EU **Relapsed Refractory Multiple Myeloma**
- ✓ EU **IMBRUVICA (ibrutinib)**
Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) (GLOW)
- ✓ US **IMBRUVICA (ibrutinib)**
Pediatric Chronic Graft Versus Host Disease
- ✓ US **teclistamab (BCMA/CD3)**
- ✓ EU **Relapsed Refractory Multiple Myeloma**
- ✓ US **CABENUVA**
HIV Adolescents
- ✓ US **STELARA (ustekinumab)**
Pediatric Juvenile Psoriatic Arthritis

PLANNED SUBMISSIONS US/EU

- ✓ EU **IMBRUVICA (ibrutinib)**
Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (SHINE)
- ✓ EU **teclistamab (BCMA/CD3)**
Relapsed Refractory Multiple Myeloma
- ✓ US **IMBRUVICA (ibrutinib)**
Pediatric Chronic Graft Versus Host Disease
- ✓ EU **niraparib**
L1 Prostate cancer metastatic castration-resistant in combination with abiraterone acetate and Prednisone
- ✓ US **talquetamab**
Relapsed Refractory Multiple Myeloma
- ✓ US **ERLEADA (apalutamide)**
- ✓ EU **Tablet Reduction**
- ✓ US **aproцитentan**
Difficult to treat hypertension

POTENTIAL CLINICAL DATA

Phase III

- ✓ **niraparib**
L1 Prostate cancer metastatic castration-resistant (MAGNITUDE)
- ✓ **aproцитentan**
Difficult to treat hypertension (PRECISION RHTT)

Phase II

- ✓ **BALVERSA (erdafitinib)**
Tumor Agnostic (RAGNAR)
- ✓ **milvexian (factor Xla)**
Secondary stroke prevention (AXIOMATIC-SSP)
- ✓ **guselkumab/golimumab**
Ulcerative Colitis (VEGA)
- ✓ **guselkumab**
Ulcerative Colitis Monotherapy (QUASAR)
- ✓ **talquetamab**
Relapsed Refractory Multiple Myeloma

*This information is accurate as of January 24, 2023 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.



✓ = Achieved